Commodore Capital’s Enliven Therapeutics ELVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$128M Sell
3,275,000
-1,417,809
-30% -$39.3M 7.43% 3
2025
Q4
$72.3M Hold
4,692,809
4.81% 7
2025
Q3
$96.1M Hold
4,692,809
4.69% 5
2025
Q2
$94.1M Buy
4,692,809
+17,809
+0.4% +$337K 6.64% 4
2025
Q1
$92M Buy
4,675,000
+470,000
+11% +$10.1M 6.78% 3
2024
Q4
$94.6M Buy
4,205,000
+105,000
+3% +$2.72M 6.93% 5
2024
Q3
$105M Buy
4,100,000
+126,755
+3% +$2.94M 6.54% 5
2024
Q2
$92.9M Hold
3,973,245
6.34% 5
2024
Q1
$69.9M Buy
3,973,245
+1,071,429
+37% +$16.4M 4.67% 6
2023
Q4
$40.2M Hold
2,901,816
3.51% 12
2023
Q3
$39.6M Buy
2,901,816
+553,544
+24% +$9.32M 4.63% 8
2023
Q2
$47.9M Buy
2,348,272
+616,907
+36% +$12.5M 5.39% 10
2023
Q1
$37.9M Buy
1,731,365
+1,107,666
+178% +$22.5M 5.77% 7
2022
Q4
$10.2M Buy
+623,699
New +$9.97M 1.54% 23

Other funds holding ELVN